Duong Benjamin
Nemours Children's Health Delaware, Precision Medicine, Clinical Pharmacogenomics Service.
Dela J Public Health. 2021 Dec 15;7(5):12-15. doi: 10.32481/djph.2021.12.006. eCollection 2021 Dec.
Pharmacogenetics allows providers to enhance their treatment decisions for common medications used in certain conditions such as depression, gastroesophageal reflux disease (GERD), pain, and acute lymphoblastic leukemia. A precision medicine approach combines pharmacogenetics (when appropriate) with other clinical and environmental factors to minimize trial-and-error of treatment. Public awareness of the impact of pharmacogenetics on treatment decisions is growing, and healthcare should be aware of the resources supporting it. Pharmacogenetics may seem daunting, but the accessibility of pharmacogenetic testing has improved with growing availability of evidence-based clinical recommendations, pharmacogenetic tests, clinical decision support resources, insurance coverage, and digestible education materials. As precision medicine and precision public health expands over the next decade, pharmacogenetic testing will continuously grow to be cheaper and part of routine genetic or genomic screenings, and be another common test-like liver or kidney function tests-that can enhance treatment decisions.
药物遗传学使医疗服务提供者能够优化针对某些病症（如抑郁症、胃食管反流病（GERD）、疼痛和急性淋巴细胞白血病）常用药物的治疗决策。精准医学方法将药物遗传学（在适当情况下）与其他临床和环境因素相结合，以尽量减少治疗的反复试验。公众对药物遗传学对治疗决策影响的认识正在提高，医疗保健行业应了解支持它的资源。药物遗传学可能看起来令人生畏，但随着循证临床建议、药物遗传学检测、临床决策支持资源、保险覆盖范围和易于理解的教育材料越来越容易获得，药物遗传学检测的可及性已有所改善。随着精准医学和精准公共卫生在未来十年的扩展，药物遗传学检测将持续变得更便宜，并成为常规基因或基因组筛查的一部分，成为另一种像肝肾功能检测一样能优化治疗决策的常见检测。
